An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies

Clin Transl Med. 2021 Nov;11(11):e572. doi: 10.1002/ctm2.572.
No abstract available

Publication types

  • Letter

MeSH terms

  • Amino Acid Oxidoreductases / analysis
  • Amino Acid Oxidoreductases / pharmacology*
  • Amino Acid Oxidoreductases / therapeutic use
  • Antifibrotic Agents / analysis
  • Antifibrotic Agents / pharmacology*
  • Antifibrotic Agents / therapeutic use
  • Biosensing Techniques / instrumentation*
  • Biosensing Techniques / methods
  • Biosensing Techniques / standards*
  • Fibrosis / drug therapy
  • Fibrosis / prevention & control
  • Humans

Substances

  • Antifibrotic Agents
  • Amino Acid Oxidoreductases
  • LOXL2 protein, human